Halozyme's strategic acquisition of Evotec and innovative ENHANZE technology present growth opportunities. Click here for a ...

ADRs quickly plunged 9% in premarket trading amid a report that the company is preparing to fight back against Halozye ...

Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, ...

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where Evotec SE (NASDAQ:EVO) stands against the other German stocks. In Germany, ...

Halozyme Therapeutics (NASDAQ:HALO) fell 14% after confirming on Thursday that it made an €11 per share bid for Evotec .

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer ...

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA’s ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

To compile our list of the best German stocks to buy, we first made a list of all German firms that are trading on the NASDAQ ...

Following the announcement, US-listed shares of Evotec rose by nearly 7%, while Halozyme's shares declined by 4.5% in premarket trading Friday. Evotec’s shares in Frankfurt jumped more than 20%.